From MVP to Series A: HealthTech Architecture Decisions That Investors Don't Like

HealthTech companies have raised $11.5 billion in equity funding across 533 rounds in 2026 so far, a 13.7% rise compared to the same period last year. The money is there. But out of more than 142,000 HealthTech companies globally, only 10,906 have reached Series A or higher.

That gap is not entirely explained by product quality. A large part of it is explained by what investors find when they look under the hood.

Series A technical due diligence in HealthTech is different from standard SaaS diligence.

It is not just about whether the code is clean or the system can handle load. It is about whether the architecture can carry clinical data safely at scale, pass a hospital security audit, and stand up to the regulatory requirements that come with any real enterprise health system contract.

Most founders know the product criteria. Far fewer know exactly what the technical criteria look like in practice. This guide covers every architecture decision that investors check, and what to do if yours does not hold up.

Why HealthTech Diligence Is Harder Than Standard SaaS Diligence

A standard SaaS technical diligence review asks: is this system stable, scalable, and defensible?

A HealthTech technical diligence review asks all of that plus:

• Is every system that handles Protected Health Information (PHI) compliant with HIPAA?
• Can this architecture integrate with major EHR systems without a full rebuild?
• Is the compliance infrastructure documented well enough to survive an OCR audit or a hospital IT security review?
• Is there meaningful technical debt that will delay or prevent a hospital contract from going live?
• Does this codebase reflect genuine healthcare domain knowledge or was it built by a generalist team that learned HIPAA along the way?

The successful Series A in 2026 is defined by technical defensibility and evidence maturity. Investors no longer prioritise raw user acquisition. They demand regulatory fortitude and a clear line of sight to measurable ROI within healthcare systems.

The founders who get through technical diligence cleanly are the ones who built with investors as a secondary audience from the first sprint, not the ones who built the product and then prepared for diligence two weeks before a term sheet.

7 Major Architecture Decisions Investors Check First

1. How HIPAA Infrastructure Was Built

This is the first line of investigation in any HealthTech diligence. Not whether you are HIPAA compliant in a general sense. Whether compliance was built into the architecture from the beginning or bolted on after the product was built.

What investors look for:

• Encryption at rest and in transit implemented as a structural feature, not a configuration setting applied after deployment
• Audit logging for every access to PHI: who accessed what, when, from which system, and with what result
• Role-based access controls (RBAC) that reflect actual clinical role structures rather than a generic admin and user model
• Business Associate Agreements (BAAs) signed with every third-party service that touches PHI including cloud provider, analytics tools, communication platforms, and any AI services
• A documented HIPAA risk assessment that covers the specific product architecture, not a generic template

What raises a red flag:

• Compliance documentation that was clearly written after the product was built
• Encryption applied inconsistently across different data stores
• No audit log system or audit logs that only capture login events rather than data access events
• Missing BAAs with vendors that are clearly in scope

The cost of getting this wrong: A non-compliant architecture found during hospital procurement or investor diligence does not pause the process. It ends it. Rebuilding a compliant data layer after the fact costs $60,000 to $120,000 and typically three to six months.

2. Scalability of the Data Architecture

Investors are not just evaluating where your product is today. They are evaluating whether the architecture can carry 10x or 100x the current load without a structural rebuild.

What investors examine:

• Database design: relational versus NoSQL choices and whether they are appropriate for your specific data access patterns
• Stateless versus stateful service architecture and whether the application layer can be scaled horizontally
• Whether PHI data and non-PHI data are appropriately separated at the schema level
• Whether clinical data models are designed for the specific requirements of health data (temporal data, clinical coding systems, patient identity management) or treated as generic application data

Common problems diligence finds:

• A single monolithic database that works fine at pilot scale but will require complete re-architecture for enterprise deployment
• Clinical data stored in a format that makes EHR integration extremely difficult to add later
• No separation between patient identity data and clinical content, making data governance and access controls hard to implement correctly

3. EHR Integration Readiness

Interoperability readiness with FHIR R4 and TEFCA alignment is now an explicit Series A investment criterion. If your product cannot connect to Epic, Cerner, or AthenaHealth, your addressable market is every hospital that will build an entirely new system around your product. That is a very small market.

What investors check:

• Whether the architecture has a clean integration layer that separates your core product logic from EHR-specific implementation details
• Whether FHIR R4 resources are a first-class part of your data model or whether EHR integration would require rebuilding how data is structured
• Whether you have an existing Epic sandbox or Cerner developer registration, indicating you have at least started the integration process
• Whether your patient identity model uses standard identifiers (MRN, national identifiers) that map naturally to EHR patient records

What the absence of EHR readiness signals to investors:

It signals that the team does not understand how hospital technology procurement works. Hospitals do not replace their EHR. They add products that connect to it. A product with no credible integration pathway is a product that hospitals cannot buy, regardless of clinical value.

4. Security Posture and Documentation

PE firms in New York and Boston, and VCs in San Francisco, increasingly require SOC 2 compliance as a baseline requirement for any deal above $10 million.

What investors want to see:

• SOC 2 Type II report (or Type I at minimum, with Type II in progress)
• A penetration test conducted within the last 12 months by a qualified third party
• A documented vulnerability management process: how vulnerabilities are found, prioritised, and resolved
• Infrastructure-as-code (IaC) for all environments, so the security configuration of production is version-controlled and auditable rather than applied manually per deployment
• Separate environments for development, staging, and production, with PHI confined to production only

What raises concerns:

• SOC 2 Type I that was completed the month before the diligence process started
• A penetration test that found critical vulnerabilities with no documented remediation
• Manual infrastructure setup with no IaC, meaning there is no reliable way to replicate or audit the production security configuration
• Development environments that contain real patient data

5. Technical Debt: How Much and What Kind

Technical debt in HealthTech is not just an engineering problem. It is a regulatory and commercial problem.

What investors assess:

• The ratio of feature code to infrastructure and compliance code, which indicates how much of the build budget went into the product versus the regulated layer
• Whether the codebase has meaningful test coverage, specifically for clinical logic and data handling functions
• Dependency management: are third-party libraries current, and are there known vulnerabilities in the dependency tree?
• Documentation quality: can a new engineer understand how the system works from the existing documentation, or is the knowledge locked in the heads of the founding team?

The specific HealthTech technical debt investors worry most about:

• Clinical logic embedded directly in UI code rather than in a tested, versioned service layer
• Compliance controls implemented as application-level checks rather than as infrastructure-level controls, meaning a code deployment can inadvertently bypass them
• Hardcoded PHI handling that assumes a specific clinical workflow and cannot adapt to the variation across different hospital environments

Read More: Full Breakdown of What FHIR R4 Need for Startups in 2026

6. Regulatory Classification and Documentation

A believable regulatory plan tied to FDA pathways is now an explicit investment criterion at Series A.

What investors check:

• Has the team determined whether the product is a Software as a Medical Device (SaMD)?
• If SaMD: is there a documented regulatory pathway and is the team on it?
• If not SaMD: is there written documentation explaining why not, in terms that would hold up to FDA scrutiny?
• For UK-based products: MHRA registration status
• For GCC products: SFDA or MOHAP classification status

What founders often get wrong:

Ignoring the regulatory classification question entirely and assuming that a non-clearance product is automatically not a SaMD. Investors bring regulatory advisors into diligence specifically to challenge this assumption. A product that qualifies as SaMD but has no regulatory plan is a liability, not a feature.

7. Cloud Architecture and Infrastructure Choices

What investors evaluate:

• Whether the cloud provider and specific services used are HIPAA-eligible with a signed BAA
• Whether the infrastructure can be deployed into additional cloud regions or countries to support international expansion (important for products targeting GCC or UK NHS or markets alongside the US)
• Whether the deployment pipeline is automated and repeatable, or whether production deployments are manual processes that introduce risk
• Cost efficiency at scale: does the infrastructure cost structure make financial sense at 10x current volume?

Common problems found:

• Product built on a general-purpose cloud region without verifying HIPAA eligibility of every service in use
• No disaster recovery plan that is documented, tested, and achieves clinical recovery time objectives
• Manual deployment processes with no rollback capability

What Investors Are Not Checking (But Should Still Exist)

These items do not always appear on a diligence checklist but their absence creates friction in the conversation:

• A documented on-call process for production incidents affecting PHI
• A defined process for handling data subject access requests (relevant for UK GDPR and increasingly for US state privacy laws)
• Version history of your HIPAA risk assessment showing it has been updated as the product changed
• A breach notification procedure that names specific roles and timelines rather than referring generically to "notifying relevant parties"

Read More: How Much Does It Cost to Build a HealthTech MVP in 2026? (Full Breakdown)

Pre-Diligence Checklist: Fix These Before the Conversation Starts

Use this to identify and address gaps before your first investor technical review.

Conclusion

Series A in HealthTech is not won on a good demo. It is won on what sits behind it.

Investors in 2026 are looking for founders who treated compliance, scalability, and interoperability as engineering requirements from day one, not problems to solve once funding arrives. Every architecture decision covered in this guide is something a technical diligence team will check. Some take weeks to fix. Some take months.

The founders who move fastest through diligence are the ones who already have the answers ready. Not because they got lucky, but because they built with that scrutiny in mind from the very first sprint.

Start there.